Biotech Sector Booms as Oncology Drugs Market Projected to Reach $700 Billion by 2034
The biotech sector is experiencing significant growth as companies invest heavily in oncology therapeutics. According to BioPharma Dive, over $3.9 billion of the $9 billion flowing into venture capital-funded biotechs in the first half of 2026 went towards cancer and immunology drugs. This accounts for more than 40% of total funds raised.
The global oncology drugs market is projected to grow from $256.5 billion in 2025 to almost $700 billion by 2034, representing an 11.8% CAGR as predicted by Fortune Business Insights.
Several biotech companies are leading the way in cancer drug development. Moderna's personalized cancer therapy has met its primary endpoint of recurrence-free survival in a Phase III melanoma study when combined with Merck's Keytruda. Amgen is expanding its oncology footprint through both established products and a deep pipeline.
Illumina occupies a critical position in the oncology ecosystem as a provider of genomic tools enabling precision medicine. Iovance Biotherapeutics has translated tumor-infiltrating lymphocyte therapy into commercial reality, and Halozyme Therapeutics provides enabling technology that enhances how oncology drugs are delivered.